ZEAL Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.…
Industry Peers
BiotechnologyKey Statistics
About Zealand Pharma (CPH: ZEAL)
›
Zealand Pharma (CPH: ZEAL) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 605 employees.
The shares were at 212.70 DKK on 19 November 2026, down 51.2% over 52 weeks. Its 52-week range is 212.70 DKK to 556.00 DKK, and it trades at the bottom of that range.
At a market capitalisation of 14.11B DKK, it trades at 4.8 times trailing earnings and 29.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 86% for ZEAL.
Zealand Pharma reports return on equity of 43.5%, an operating margin of 59.0% and revenue down 92.0% year over year.
It holds more cash than debt, a net cash position of 13.03B DKK. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 383.58 DKK is 80.3% above the current price. The next earnings report is expected on 25 February 2027.